Navitas Life Sciences

Highly Efficient Safety and Efficacy Evaluation of COVID-19 Therapies in Moderate to Severe Patients

Our client, a multinational mid-sized pharma company needed assistance in running a clinical trial to evaluate the safety and efficacy of an adjunctive therapy in the acute treatment of moderate to severe COVID-19 patients.

Read our latest case study and learn how we are driving operational approaches to evaluate the safety and efficacy of their therapies in moderate to severe COVID-19 patients. From being awarded the studies to date we have:

  • Quickly activated sites within 20 days
  • Achieved FPI within 30 days of study award
  • Recruited Patients ahead of time
  • Comprehensive trial oversight through our in-house analytics platform

Please complete the form to download our case study.

Please complete form to download PDF
First Name
Last Name
Business Email
Company
Job Title
Country
By submitting this form, I agree to receive email communications from Navitas Life Sciences. Privacy Policy | EU-US & Swiss-US Privacy Shield Policy

© 2020 Navitas Life Sciences | A TAKE Solutions Enterprise  
Privacy Policy EU-US & Swiss-US Privacy Shield Policy